Physician profile
Reshma S Parab
NPI 1073549325
$5,531.25
in general payments reported to CMS, 2019-2025
36 companies · $782 in 2025
The $782 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $622 · 2020: $142 · 2021: $453 · 2022: $2,642 · 2023: $453 · 2024: $438 · 2025: $782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,633 · Long Term Medical Supply Or Device Loan: $39.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,632.65 |
| Long Term Medical Supply Or Device Loan | $39.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,230.85 | 2021-2025 | Minimed 780g |
| Lilly USA, LLC | $480.12 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $334.36 | 2019-2025 | Ozempic, Rybelsus |
| Ibsa Pharma INC. | $309.60 | 2019-2025 | Tirosint, Licart, Tirosint |
| Boehringer Ingelheim Pharmaceuticals, INC. | $299.79 | 2019-2025 | Jardiance, Tradjenta |
| Abbott Laboratories | $254.39 | 2021-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Xeris Pharmaceuticals, INC. | $209.22 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Insulet Corporation | $160.42 | 2019-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $156.20 | 2019-2025 | |
| Lifescan, INC. | $154.56 | 2020-2023 | |
| Amneal Pharmaceuticals LLC | $122.73 | 2019-2025 | Unithroid |
| Amgen INC. | $105.23 | 2019-2025 | Evenity, Prolia |
| Tandem Diabetes Care, INC. | $60.48 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Averitas Pharma INC. | $58.80 | 2025 | Qutenza |
| Abbvie INC. | $54.72 | 2021-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $53.11 | 2025 | Vyepti |
| Corcept Therapeutics | $44.71 | 2024 | Korlym |
| Dexcom, INC. | $42.93 | 2019-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $42.27 | 2021-2022 | |
| Sk Life Science, INC. | $30.89 | 2025 | |
| Intuity Medical INC | $30.74 | 2022 | |
| Janssen Pharmaceuticals, INC | $30.43 | 2022 | |
| Medtronic Minimed, INC. | $27.87 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.25 | 2025 | |
| Ascensia Diabetes Care US INC. | $23.20 | 2025 | |
| Antares Pharma, INC. | $21.12 | 2019 | |
| Horizon Therapeutics Plc | $20.87 | 2023 | Tepezza |
| Becton, Dickinson and Company | $20.85 | 2019 | |
| Azurity Pharmaceuticals, INC. | $19.94 | 2025 | Azmiro |
| Valeritas, INC. | $17.47 | 2019 | |
| Endo Pharmaceuticals INC. | $17.28 | 2019 | |
| Neurelis, INC. | $17.18 | 2025 | Valtoco |
| Bayer Healthcare Pharmaceuticals INC. | $14.24 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.09 | 2023 | Gattex |
| Clarus Therapeutics INC. | $14.04 | 2021 | |
| Merck Sharp & Dohme LLC | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reshma Parab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.